| Cat.No. | Name | Information |
|---|---|---|
| M1825 | PCI-32765 | PCI-32765 (Ibrutinib) is a potent, selective and orally bioavailable irreversible inhibitor of BTK with IC50 value of 0.46 nM. |
| M43474 | BTK-IN-25 | BTK-IN-25 is a potent inhibitor of BTK, and inhibits BTK(C481S) with an IC50 value of 0.77 nM. |
| M43473 | Cinsebrutinib | Cinsebrutinib is a Bruton's tyrosine kinase inhibitor, extracted from patent WO2021207549 (compound 5-6). |
| M43472 | BTK-IN-26 | BTK-IN-26 is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC50 values of 0.7 and 0.8 nM for BTK and BTK C481S, respectively. |
| M43406 | PROTAC BTK Degrader-6 | PROTAC BTK Degrader-6 is a PROTAC BTK degrader (DC50: 3.18 nM. |
| M40617 | TAS5315 | TAS5315 is a novel, irreversible covalent inhibitor of BTK for studies related to rheumatoid arthritis. |
| M29609 | JS25 | JS25 is a selective and covalent inhibitor of BTK that inactivates BTK with an IC50 value of 5.8 nM by chelating Tyr551. JS25 inhibits cancer cells proliferation, pronounces cell death, and promotes murine xenograft model of Burkitt’s lymphoma. JS25 effectively crosses the blood-brain barrier. |
| M29480 | BGB-8035 | BGB-8035 is an orally active, highly selective bruton's tyrosine kinase (BTK) inhibitor with IC50s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research. |
| M29210 | CHMFL-BTK-01 | CHMFL-BTK-01 (compound 9) is a highly selective irreversible BTK inhibitor, with an IC50 of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation. |
| M28957 | BTK inhibitor 17 | BTK inhibitor 17 is a potent and orally active irreversible BTK inhibitor with an IC50 of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research. |
| M28956 | Edralbrutinib | Edralbrutinib (TG-1701) is a potent, novel, orally active, irreversible BTK inhibitor that selectively inhibits the activation, proliferation, and survival of B cells, and can act on other immune cells, such as macrophages, to influence the autoimmune inflammatory process mediated by B cells and other immune cells, and can be used in the study of optic neuromyelitis optica spectrum disorders (NMOSD). |
| M28901 | CHMFL-BMX-078 | CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM. |
| M28865 | BIIB068 | BIIB068 is a potent, selective, reversible and orally active BTK inhibitor with an IC50 of 1 nM and a Kd of 0.3 nM. BIIB068 shows more >400-fold selective for BTK than other kinases. BIIB068 has the potential for autoimmune diseases research. |
| M28767 | Elsubrutinib | Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor。The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease. |
| M28664 | PF-06250112 | PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5 nM, shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC with IC50s of 0.9 nM and 1.2 nM, respectively. |
| M28627 | Atuzabrutinib | Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling. |
| M28507 | QL47 | QL47, a broad-spectrum antiviral agent, inhibits dengue virus and other RNA viruses. QL47 selectively inhibits eukaryotic translation. QL47 is a potent covalent inhibitor of BTK with an IC50 of 7 nM. |
| M28212 | G-744 | G-744 is a highly potent, selective and orally active Btk inhibitor with an IC50 of 2 nM. G-744 is metabolically stable, well tolerated and efficacious to treat arthritis. |
| M28101 | BTK IN-1 | BTK IN-1 (SNS062 analog) is a potent BTK inhibitor, with an IC50 of <100 nM. |
| M21293 | BCPyr | BCPyr is a new candidate BTK degradation agent (DC50 = 800 nM). |
| M21284 | BMS-986143 | BMS-986143 is a potent, reversible inhibitor of tyrosine kinase (BTK), which has been successfully targeted by a number of irreversible tumor compounds. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
